Literature DB >> 17071173

A comparison of open and laparoscopic Roux-en-Y gastric bypass surgery for morbid and super obesity: a decision-analysis model.

Ali Siddiqui1, Edward Livingston, Sergio Huerta.   

Abstract

BACKGROUND: The aim of this study was to compare laparoscopic Roux-en-Y gastric bypass (LGBP) with open Roux-en-Y gastric bypass (OGBP) to determine which approach resulted in better clinical outcomes and cost effectiveness in patients with morbid obesity.
METHODS: A decision-analysis model was constructed to evaluate outcomes of LGBP versus OGBP in patients with body mass index (BMI) ranges of 35 to 49, 50 to 60, and greater than 60. Baseline assumptions for the model were derived from published reports. Sensitivity and cost-effectiveness analyses were performed to determine the optimal strategy. Success was defined as no major procedure-related complications and no long-term complications over a 1-year period after surgery. Failure of therapy was defined as either recurrent symptoms or death attributed to a surgical complication.
RESULTS: In patients with a BMI of 35 to 49, LGBP failed in 14% and OGBP failed in 18% of patients, favoring LGBP alone as the dominant strategy. Mortality in the OGBP group was 1.3 times that of the LGBP group. For a BMI of 50 to 60, LGBP was dominant with an overall success rate of 82% as compared with OGBP (77%). Mortality in the OGBP group was 1.3 times that of the LGBP group. For a BMI of greater than 60, LGBP was the dominant strategy with an overall success rate of 67% compared with OGBP (63%). Sensitivity and cost-effective analysis showed that LGBP was the dominant strategy in terms of greater success and less overall morbidity and mortality for all 3 groups.
CONCLUSIONS: This analysis suggests that for all BMI ranges evaluated, LGBP is preferable to OGBP. These conclusions are limited by potential selection and publication bias in the trials assessed for this analysis. These limitations can be resolved only by randomized control trials.

Entities:  

Mesh:

Year:  2006        PMID: 17071173     DOI: 10.1016/j.amjsurg.2006.08.023

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  7 in total

1.  Commentary re: laparoscopic versus open gastric bypass.

Authors:  Kenneth B Jones
Journal:  Obes Surg       Date:  2009-12-12       Impact factor: 4.129

Review 2.  Development of ulcer disease after Roux-en-Y gastric bypass, incidence, risk factors, and patient presentation: a systematic review.

Authors:  Usha K Coblijn; Amin B Goucham; Sjoerd M Lagarde; Sjoerd D Kuiken; Bart A van Wagensveld
Journal:  Obes Surg       Date:  2014-02       Impact factor: 4.129

Review 3.  Robotic versus laparoscopic Roux-en-Y gastric bypass (RYGB) in obese adults ages 18 to 65 years: a systematic review and economic analysis.

Authors:  Jonathan G Bailey; Jill A Hayden; Philip J B Davis; Richard Y Liu; David Haardt; James Ellsmere
Journal:  Surg Endosc       Date:  2013-10-03       Impact factor: 4.584

4.  Complications After Laparoscopic Roux-en-Y Gastric Bypass in 1573 Consecutive Patients: Are There Predictors?

Authors:  Anna Dayer-Jankechova; Pierre Fournier; Pierre Allemann; Michel Suter
Journal:  Obes Surg       Date:  2016-01       Impact factor: 4.129

5.  Silicone-ring Roux-en-Y gastric bypass in the treatment of obesity: effects of laparoscopic versus laparotomic surgery on respiration.

Authors:  Marcela Cangussu Barbalho-Moulim; Gustavo Peixoto Soares Miguel; Eli Maria Pazzianotto Forti; Marcelo de Castro César; João Luiz Moreira Coutinho Azevedo; Dirceu Costa
Journal:  Obes Surg       Date:  2009-03-21       Impact factor: 4.129

6.  Does route of hysterectomy affect outcome in obese and nonobese women?

Authors:  Paul R Brezina; Todd M Beste; Keith H Nelson
Journal:  JSLS       Date:  2009 Jul-Sep       Impact factor: 2.172

Review 7.  Systematic review of economic evaluation of laparotomy versus laparoscopy for patients submitted to Roux-en-Y gastric bypass.

Authors:  Samanta Pereira Sussenbach; Everton Nunes Silva; Milene Amarante Pufal; Daniela Shan Casagrande; Alexandre Vontobel Padoin; Cláudio Corá Mottin
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.